Community-wide Consensus Process Generates a Framework for Reporting of T-cell Experiments in Clinical Immunology

Community-wide Consensus Process Generates a Framework for Reporting of T-cell Experiments in Clinical Immunology PR Newswire MAINZ, Germany and NEW YORK, July 26, 2012 MAINZ, Germany and NEW YORK, July 26, 2012 /PRNewswire/ -- Increasing transparency and quality of immune response measurements The Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP) and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) today announced the publication of a letter in Immunity discussing the results of an unique vetting process that involved multiple international groups and individuals and has now led to publication guidelines that increase transparency of immune response assessments. The finalized Minimal Information About T Cell Assays (MIATA) project, which provides a guiding framework for reporting T cell experiments in human translational monitoring studies, has been published in the current issue of thImmunity released on July 26 , 2012. The project was announced in the same journal in 2009, and has since then undergone two public consultation periods and workshops that led to the current, final guidelines that integrate the feedback of more than 120 contributors. "This was one of the most intense vetting processes conducted in the field of immunology," states lead author Cedrik Britten from Translational Oncology at the University Medical Center of the Johannes Gutenberg-University in Mainz, Germany.